can04

mAbexperimental

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07281716Phase 1/Phase 2 (Phase 2)Dec 31, 2025Cantargia AB, Coherus Oncology, Inc., Icahn School of Medicine at Mount Sinai
NCT07284485Phase 2Dec 15, 2025Cantargia AB, Icahn School of Medicine at Mount Sinai
NCT06548230Phase 1/Phase 2 (Phase 2)Jan 1, 2025University of Texas at Houston
NCT05181462Phase 1/Phase 2 (Phase 2)Jan 11, 2022Cantargia AB, Spanish Breast Cancer Research Group, University of Navarra
NCT05116891Phase 1/Phase 2 (Phase 2)Sep 22, 2021Cantargia AB
NCT04990037Phase 1Jul 31, 2021Cantargia AB
NCT04452214Phase 1Sep 24, 2020Cantargia AB
NCT03267316Phase 1/Phase 2 (Phase 2)Sep 19, 2017Cantargia AB, Free University of Brussels
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cantargia ABFor profit7522017
Icahn School of Medicine at Mount SinaiAcademic/Hospital2212025
Coherus Oncology, Inc.For profit1012025
Free University of BrusselsAcademic/Hospital1012017
Spanish Breast Cancer Research GroupAcademic/Hospital1012022
University of NavarraAcademic/Hospital1012022
University of Texas at HoustonAcademic/Hospital1112025
7 organizations
Page 1 / 1